Chief Emeritus, Division of Neurology Winthrop Comprehensive MS Care Center, NYU Langone Hospital Professor, Department of Neurology NYU Long Island School of Medicine Mineola, NY
Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medic...READ MORE
expert roundtables by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
The expansion of the multiple sclerosis (MS) treatment arsenal has led to more options for disease-modifying therapy (DMT) than ever before. Althou...READ MORE
expert roundtables by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
Additional disease-modifying therapies (DMTs) allow for greater flexibility in considering agents that vary in mechanism of action and route of adm...READ MORE
patient care perspectives by Malcolm H. Gottesman, MD
Quality of life (QOL) in patients with multiple sclerosis (MS) is influenced by disease progression and the level of disability, as well as individ...READ MORE
patient care perspectives by Malcolm H. Gottesman, MD
As the probability of active multiple sclerosis (MS) declines with age and the susceptibility to adverse effects increases, the risks vs the benefi...READ MORE
expert roundtables by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
Advancements in basic science and successful clinical trials have provided the foundation for the rapid expansion of treatment options for multiple...READ MORE
expert roundtables by Robert A. Bermel, MD, MBA; Malcolm H. Gottesman, MD; and Eric C. Klawiter, MD, MSc
From B-cell–depleting monoclonal antibodies to sphingosine-1-phosphate receptor modulators, the diversity of the available high-potency therapies i...READ MORE
clinical topic updates by Malcolm H. Gottesman, MD
An increased understanding of the pathophysiology of multiple sclerosis (MS) has led to the development and recent US Food and Drug Administration ...READ MORE
